Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 May;39(5):1045–1049. doi: 10.1128/aac.39.5.1045

Interaction study of lomefloxacin and ciprofloxacin with omeprazole and comparative pharmacokinetics.

H Stuht 1, H Lode 1, P Koeppe 1, K L Rost 1, T Schaberg 1
PMCID: PMC162680  PMID: 7625786

Abstract

To assess whether or not concomitant omeprazole treatment influences the pharmacokinetics of lomefloxacin and ciprofloxacin, a randomized, double-blind four-way-crossover study was performed. Another objective was to compare the pharmacokinetics of lomefloxacin and ciprofloxacin. Twelve healthy volunteers participated. On days 1 to 4 of each study period, each of them took 20 mg of omeprazole or a placebo orally, and on day 4, each took 400 mg of lomefloxacin or 500 mg of ciprofloxacin orally. Blood and urine samples were collected and assayed for the quinolones by high-pressure liquid chromatography. The mean peak concentrations in plasma (Cmax) and the areas under the curves (AUC), respectively, of lomefloxacin and ciprofloxacin, respectively, after prior treatment with placebo were 2.88 +/- 0.73 (mean +/- standard deviation) as against 2.60 +/- 0.76 micrograms/ml and 24.9 +/- 3.13 as against 11.9 +/- 1.89 micrograms.h/ml, and 72.4% +/- 5.10% as against 36.1% +/- 7.50% of the doses of lomefloxacin and ciprofloxacin, respectively, were recovered from the urine. None of the pharmacokinetic parameters differed significantly after prior treatment with omeprazole compared with placebo. The Cmax of lomefloxacin was not significantly higher than that of ciprofloxacin, but lomefloxacin's AUC reached twice that of ciprofloxacin because of its significantly longer half-life in plasma (6.68 +/- 1.94 as against 4.15 +/- 0.92 h, respectively, P < or = 0.01). Concomitant therapy with omeprazole did not alter the pharmacokinetics of lomefloxacin or ciprofloxacin in these single-dose studies.

Full Text

The Full Text of this article is available as a PDF (204.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andersson T., Andrén K., Cederberg C., Edvardsson G., Heggelund A., Lundborg P. Effect of omeprazole and cimetidine on plasma diazepam levels. Eur J Clin Pharmacol. 1990;39(1):51–54. doi: 10.1007/BF02657057. [DOI] [PubMed] [Google Scholar]
  2. Andersson T., Cederberg C., Edvardsson G., Heggelund A., Lundborg P. Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clin Pharmacol Ther. 1990 Jan;47(1):79–85. doi: 10.1038/clpt.1990.12. [DOI] [PubMed] [Google Scholar]
  3. Andersson T. Omeprazole drug interaction studies. Clin Pharmacokinet. 1991 Sep;21(3):195–212. doi: 10.2165/00003088-199121030-00004. [DOI] [PubMed] [Google Scholar]
  4. Barry A. L., Fass R. J., Anhalt J. P., Neu H. C., Thornsberry C., Tilton R. C., Painter B. G., Washington J. A., 2nd Ciprofloxacin disk susceptibility tests: interpretive zone size standards for 5-microgram disks. J Clin Microbiol. 1985 Jun;21(6):880–883. doi: 10.1128/jcm.21.6.880-883.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bergan T., Thorsteinsson S. B., Solberg R., Bjornskau L., Kolstad I. M., Johnsen S. Pharmacokinetics of ciprofloxacin: intravenous and increasing oral doses. Am J Med. 1987 Apr 27;82(4A):97–102. [PubMed] [Google Scholar]
  6. Borner K., Höffken G., Lode H., Koeppe P., Prinzing C., Glatzel P., Wiley R., Olschewski P., Sievers B., Reinitz D. Pharmacokinetics of ciprofloxacin in healthy volunteers after oral and intravenous administration. Eur J Clin Microbiol. 1986 Apr;5(2):179–186. doi: 10.1007/BF02013983. [DOI] [PubMed] [Google Scholar]
  7. Brumfitt W., Franklin I., Grady D., Hamilton-Miller J. M., Iliffe A. Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human volunteers. Antimicrob Agents Chemother. 1984 Nov;26(5):757–761. doi: 10.1128/aac.26.5.757. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Cederberg C., Andersson T., Skånberg I. Omeprazole: pharmacokinetics and metabolism in man. Scand J Gastroenterol Suppl. 1989;166:33–42. doi: 10.3109/00365528909091241. [DOI] [PubMed] [Google Scholar]
  9. Cox C. E. A comparison of the safety and efficacy of lomefloxacin and ciprofloxacin in the treatment of complicated or recurrent urinary tract infections. Am J Med. 1992 Apr 6;92(4A):82S–86S. doi: 10.1016/0002-9343(92)90315-3. [DOI] [PubMed] [Google Scholar]
  10. Crump B., Wise R., Dent J. Pharmacokinetics and tissue penetration of ciprofloxacin. Antimicrob Agents Chemother. 1983 Nov;24(5):784–786. doi: 10.1128/aac.24.5.784. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Davis R. L., Koup J. R., Williams-Warren J., Weber A., Smith A. L. Pharmacokinetics of three oral formulations of ciprofloxacin. Antimicrob Agents Chemother. 1985 Jul;28(1):74–77. doi: 10.1128/aac.28.1.74. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Garrelts J. C., Godley P. J., Peterie J. D., Gerlach E. H., Yakshe C. C. Sucralfate significantly reduces ciprofloxacin concentrations in serum. Antimicrob Agents Chemother. 1990 May;34(5):931–933. doi: 10.1128/aac.34.5.931. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Gonzalez M. A., Uribe F., Moisen S. D., Fuster A. P., Selen A., Welling P. G., Painter B. Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers. Antimicrob Agents Chemother. 1984 Nov;26(5):741–744. doi: 10.1128/aac.26.5.741. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Grasela T. H., Jr, Schentag J. J., Sedman A. J., Wilton J. H., Thomas D. J., Schultz R. W., Lebsack M. E., Kinkel A. W. Inhibition of enoxacin absorption by antacids or ranitidine. Antimicrob Agents Chemother. 1989 May;33(5):615–617. doi: 10.1128/aac.33.5.615. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Grimm H. In vitro study with ciprofloxacin: interpretive criteria of agar diffusion test according to standards of the NCCLS and DIN. Am J Med. 1987 Apr 27;82(4A):376–380. [PubMed] [Google Scholar]
  16. Gugler R., Jensen J. C. Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterology. 1985 Dec;89(6):1235–1241. [PubMed] [Google Scholar]
  17. Healy D. P., Schoenle J. R., Stotka J., Polk R. E. Lack of interaction between lomefloxacin and caffeine in normal volunteers. Antimicrob Agents Chemother. 1991 Apr;35(4):660–664. doi: 10.1128/aac.35.4.660. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Höffken G., Borner K., Glatzel P. D., Koeppe P., Lode H. Reduced enteral absorption of ciprofloxacin in the presence of antacids. Eur J Clin Microbiol. 1985 Jun;4(3):345–345. doi: 10.1007/BF02013667. [DOI] [PubMed] [Google Scholar]
  19. Jensen J. C., Gugler R. Inhibition of human liver cytochrome P-450 by omeprazole. Br J Clin Pharmacol. 1986 Mar;21(3):328–330. doi: 10.1111/j.1365-2125.1986.tb05199.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Koeppe P., Hamann C. A program for non-linear regression analysis to be used on desk-top computers. Comput Programs Biomed. 1980 Dec;12(2-3):121–128. doi: 10.1016/0010-468x(80)90058-6. [DOI] [PubMed] [Google Scholar]
  21. Lagerström P. O., Persson B. A. Determination of omeprazole and metabolites in plasma and urine by liquid chromatography. J Chromatogr. 1984 Aug 10;309(2):347–356. doi: 10.1016/0378-4347(84)80042-0. [DOI] [PubMed] [Google Scholar]
  22. Lettieri J. T., Rogge M. C., Kaiser L., Echols R. M., Heller A. H. Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses. Antimicrob Agents Chemother. 1992 May;36(5):993–996. doi: 10.1128/aac.36.5.993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Mant T. G. Multiple-dose pharmacokinetics of lomefloxacin: rationale for once-a-day dosing. Am J Med. 1992 Apr 6;92(4A):26S–32S. doi: 10.1016/0002-9343(92)90304-t. [DOI] [PubMed] [Google Scholar]
  24. Maton P. N. Omeprazole. N Engl J Med. 1991 Apr 4;324(14):965–975. doi: 10.1056/NEJM199104043241406. [DOI] [PubMed] [Google Scholar]
  25. Mayer K. H., Ellal J. A. Lomefloxacin: microbiologic assessment and unique properties. Am J Med. 1992 Apr 6;92(4A):58S–62S. doi: 10.1016/0002-9343(92)90311-x. [DOI] [PubMed] [Google Scholar]
  26. Morrison P. J., Mant T. G., Norman G. T., Robinson J., Kunka R. L. Pharmacokinetics and tolerance of lomefloxacin after sequentially increasing oral doses. Antimicrob Agents Chemother. 1988 Oct;32(10):1503–1507. doi: 10.1128/aac.32.10.1503. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Morse I. S. Pharmacokinetics and safety of single oral doses of lomefloxacin. Biopharm Drug Dispos. 1990 Aug-Sep;11(6):543–551. doi: 10.1002/bdd.2510110608. [DOI] [PubMed] [Google Scholar]
  28. Nix D. E., Watson W. A., Lener M. E., Frost R. W., Krol G., Goldstein H., Lettieri J., Schentag J. J. Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin. Clin Pharmacol Ther. 1989 Dec;46(6):700–705. doi: 10.1038/clpt.1989.207. [DOI] [PubMed] [Google Scholar]
  29. Oosterhuis B., Jonkman J. H. Omeprazole: pharmacology, pharmacokinetics and interactions. Digestion. 1989;44 (Suppl 1):9–17. doi: 10.1159/000200098. [DOI] [PubMed] [Google Scholar]
  30. Peck C. C., Sheiner L. B., Nichols A. I. The problem of choosing weights in nonlinear regression analysis of pharmacokinetic data. Drug Metab Rev. 1984;15(1-2):133–148. doi: 10.3109/03602538409015060. [DOI] [PubMed] [Google Scholar]
  31. Prichard P. J., Walt R. P., Kitchingman G. K., Somerville K. W., Langman M. J., Williams J., Richens A. Oral phenytoin pharmacokinetics during omeprazole therapy. Br J Clin Pharmacol. 1987 Oct;24(4):543–545. doi: 10.1111/j.1365-2125.1987.tb03209.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Rost K. L., Brösicke H., Heinemeyer G., Roots I. Specific and dose-dependent enzyme induction by omeprazole in human beings. Hepatology. 1994 Nov;20(5):1204–1212. [PubMed] [Google Scholar]
  33. Shimada J., Shiba K., Oguma T., Miwa H., Yoshimura Y., Nishikawa T., Okabayashi Y., Kitagawa T., Yamamoto S. Effect of antacid on absorption of the quinolone lomefloxacin. Antimicrob Agents Chemother. 1992 Jun;36(6):1219–1224. doi: 10.1128/aac.36.6.1219. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Stone J. W., Andrews J. M., Ashby J. P., Griggs D., Wise R. Pharmacokinetics and tissue penetration of orally administered lomefloxacin. Antimicrob Agents Chemother. 1988 Oct;32(10):1508–1510. doi: 10.1128/aac.32.10.1508. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Wolfson J. S., Hooper D. C. Pharmacokinetics of quinolones: newer aspects. Eur J Clin Microbiol Infect Dis. 1991 Apr;10(4):267–274. doi: 10.1007/BF01967000. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES